Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations
CONCLUSIONS: Together, this approach offers a potential treatment strategy for patients with EGFRm-driven NSCLC that have a sub-optimal response, or develop resistance, to osimertinib through PIK3CA/AKT/PTEN alterations.PMID:38630555 | DOI:10.1158/1078-0432.CCR-23-2540 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O'Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclova Matthew J Martin Ludovic Bigot Luc Friboulet Ryan Hartmaier Maria Emanuela Cuomo Simon T Barry Paul D Smith Nicolas Floc'h Source Type: research
Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps
CONCLUSIONS: NETosis is induced by low-dose ionizing irradiation in a neutrophil-intrinsic fashion and radiation-induced NETs are able to interfere with immune-mediated cytotoxicity. Radiation-induced NETs foster metastasis in mouse models and can be detected in the circulation of patients undergoing conventional radiotherapy treatments.PMID:38630754 | DOI:10.1158/1078-0432.CCR-23-3860 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Alvaro Teijeira Saray Garasa Maria C Ochoa Sandra Sanchez-Gregorio Gabriel Gomis Carlos Luri-Rey Rafael Martinez-Monge Beatrice Pinci Karmele Valencia Belen Palencia Benigno Barbes Elixabet Bolanos Arantza Azpilikueta Marina Garcia-Cardosa Javier Burguete Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
CONCLUSIONS: FAP-IL2v had a manageable safety profile and showed initial signs of antitumor activity in advanced/metastatic solid tumors.PMID:38630781 | DOI:10.1158/1078-0432.CCR-23-3567 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Neeltje Steeghs Carlos Gomez-Roca Kristoffer S Rohrberg Morten Mau-S ørensen Debbie Robbrecht Josep Tabernero Samreen Ahmed Maria E Rodriguez-Ruiz Caroline Ardeshir Daniela Schmid Nassim Sleiman Carl Watson Hanna Piper-Lepoutre David Dejardin Stefan Ever Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
CONCLUSIONS: GNH defines an aggressive subtype of mainly biphasic DPMs in younger patients with recurrent alterations in SETDB1 and TP53. The enrichment in biphasic histology and TILs, together with our preliminary ICB response data and anecdotal clinical trial data, suggests that further evaluation of immunotherapy may be warranted in this subset.PMID:38630790 | DOI:10.1158/1078-0432.CCR-24-0085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Soo-Ryum Yang Gowtham Jayakumaran Jamal Benhamida Christopher A Febres Aldana Rachel Fanaroff Jason Chang Erika Gedvilaite Liliana B Villafania Jennifer L Sauter Michael Offin Marjorie G Zauderer Marc Ladanyi Source Type: research
Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia
CONCLUSIONS: Our study highlights the importance of considering the gene mutation patterns for the prediction of drug response in AML. It provides a framework for categorizing patients with AML by mutations that enable drug sensitivity prediction.PMID:38619278 | DOI:10.1158/1078-0432.CCR-23-1674 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 15, 2024 Category: Cancer & Oncology Authors: Guangrong Qin Jin Dai Sylvia Chien Timothy J Martins Brenda Loera Quy H Nguyen Melanie L Oakes Bahar Tercan Boris Aguilar Lauren Hagen Jeannine McCune Richard Gelinas Raymond J Monnat Ilya Shmulevich Pamela S Becker Source Type: research
Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia
CONCLUSIONS: Our study highlights the importance of considering the gene mutation patterns for the prediction of drug response in AML. It provides a framework for categorizing patients with AML by mutations that enable drug sensitivity prediction.PMID:38619278 | DOI:10.1158/1078-0432.CCR-23-1674 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 15, 2024 Category: Cancer & Oncology Authors: Guangrong Qin Jin Dai Sylvia Chien Timothy J Martins Brenda Loera Quy H Nguyen Melanie L Oakes Bahar Tercan Boris Aguilar Lauren Hagen Jeannine McCune Richard Gelinas Raymond J Monnat Ilya Shmulevich Pamela S Becker Source Type: research
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
CONCLUSIONS: Our study provides a framework for analyzing adverse events and suggests that adverse drug interactions commonly result in additive effects with a high level of overlap of adverse event patterns. These real-world insights may advance the implementation of new combination therapies in clinical practice.PMID:38597991 | PMC:PMC11016889 | DOI:10.1158/1078-0432.CCR-23-0914 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 10, 2024 Category: Cancer & Oncology Authors: Asli K üçükosmanoglu Silvia Scoarta Megan Houweling Nicoleta Spinu Thomas Wijnands Niek Geerdink Carolien Meskers Georgi K Kanev Bert Kiewiet Mathilde Kouwenhoven David Noske Tom Wurdinger Marianne Pouwer Mark Wolff Bart A Westerman Source Type: research
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
CONCLUSIONS: Our study provides a framework for analyzing adverse events and suggests that adverse drug interactions commonly result in additive effects with a high level of overlap of adverse event patterns. These real-world insights may advance the implementation of new combination therapies in clinical practice.PMID:38597991 | DOI:10.1158/1078-0432.CCR-23-0914 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 10, 2024 Category: Cancer & Oncology Authors: Asli K üçükosmanoglu Silvia Scoarta Megan Houweling Nicoleta Spinu Thomas Wijnands Niek Geerdink Carolien Meskers Georgi K Kanev Bert Kiewiet Mathilde Kouwenhoven David Noske Tom Wurdinger Marianne Pouwer Mark Wolff Bart A Westerman Source Type: research
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
CONCLUSIONS: Our study provides a framework for analyzing adverse events and suggests that adverse drug interactions commonly result in additive effects with a high level of overlap of adverse event patterns. These real-world insights may advance the implementation of new combination therapies in clinical practice.PMID:38597991 | DOI:10.1158/1078-0432.CCR-23-0914 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 10, 2024 Category: Cancer & Oncology Authors: Asli K üçükosmanoglu Silvia Scoarta Megan Houweling Nicoleta Spinu Thomas Wijnands Niek Geerdink Carolien Meskers Georgi K Kanev Bert Kiewiet Mathilde Kouwenhoven David Noske Tom Wurdinger Marianne Pouwer Mark Wolff Bart A Westerman Source Type: research
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
CONCLUSIONS: Our study provides a framework for analyzing adverse events and suggests that adverse drug interactions commonly result in additive effects with a high level of overlap of adverse event patterns. These real-world insights may advance the implementation of new combination therapies in clinical practice.PMID:38597991 | DOI:10.1158/1078-0432.CCR-23-0914 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 10, 2024 Category: Cancer & Oncology Authors: Asli K üçükosmanoglu Silvia Scoarta Megan Houweling Nicoleta Spinu Thomas Wijnands Niek Geerdink Carolien Meskers Georgi K Kanev Bert Kiewiet Mathilde Kouwenhoven David Noske Tom Wurdinger Marianne Pouwer Mark Wolff Bart A Westerman Source Type: research
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
CONCLUSIONS: Our study provides a framework for analyzing adverse events and suggests that adverse drug interactions commonly result in additive effects with a high level of overlap of adverse event patterns. These real-world insights may advance the implementation of new combination therapies in clinical practice.PMID:38597991 | DOI:10.1158/1078-0432.CCR-23-0914 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 10, 2024 Category: Cancer & Oncology Authors: Asli K üçükosmanoglu Silvia Scoarta Megan Houweling Nicoleta Spinu Thomas Wijnands Niek Geerdink Carolien Meskers Georgi K Kanev Bert Kiewiet Mathilde Kouwenhoven David Noske Tom Wurdinger Marianne Pouwer Mark Wolff Bart A Westerman Source Type: research
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
CONCLUSIONS: Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.PMID:38592373 | DOI:10.1158/1078-0432.CCR-24-0027 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Farah Ballout Heng Lu Nadeem Bhat Lei Chen Dunfa Peng Zheng Chen Steven Chen Xiaodian Sun Silvia Giordano Simona Corso Alexander Zaika Oliver McDonald Alan S Livingstone Wael El-Rifai Source Type: research
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
CONCLUSIONS: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.PMID:38592381 | DOI:10.1158/1078-0432.CCR-23-3639 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Sangini S Sheth Ji Eun Oh Stefania Bellone Eric R Siegel Michelle Greenman Levent Mutlu Blair McNamara Shefali Pathy Mitchell Clark Masoud Azodi Gary Altwerger Vaagn Andikyan Gloria Huang Elena Ratner Daniel J Kim Akiko Iwasaki Angelique W Levi Natalia Bu Source Type: research
